Elevated HSPB1 Expression Is Associated with a Poor Prognosis in Glioblastoma Multiforme Patients.

IF 0.9 4区医学 Q4 CLINICAL NEUROLOGY

Journal of neurological surgery. Part A, Central European neurosurgery Pub Date : 2024-07-03 DOI:10.1055/s-0043-1777761

Zhihua Wang, Zhaohua Fang, Yongping Gui, Bin Xi, Zhiping Xie

{"title":"Elevated HSPB1 Expression Is Associated with a Poor Prognosis in Glioblastoma Multiforme Patients.","authors":"Zhihua Wang, Zhaohua Fang, Yongping Gui, Bin Xi, Zhiping Xie","doi":"10.1055/s-0043-1777761","DOIUrl":null,"url":null,"abstract":"Background: Glioblastoma multiforme (GBM) is a highly aggressive form of brain cancer. This study investigated the clinical predictive value of heat shock protein β1 (HSPB1) in patients with GBM.Methods: A correlation was established between HSPB1 expression and GBM progression using data from The Cancer Genome Atlas (TCGA) dataset, Chinese Glioma Genome Atlas dataset, Gene Expression Omnibus dataset, and Human Protein Atlas database. A survival analysis was conducted and an HSPB1-based nomogram was constructed to evaluate the prognostic value of HSPB1 in patients with GBM.Results: Based on TCGA data mining, we discovered that HSPB1 was significantly elevated in patients with GBM and may reflect their response to immunotherapy. In survival analysis, it appeared to have a predictive role in the prognosis of patients with GBM. Five signaling pathways were significantly enriched in the high HSPB1 expression phenotype according to the gene set enrichment analysis. In addition, a significant association was found between HSPB1 expression and immune checkpoints, tumor immune infiltration, tumor immune microenvironment, and immune cell markers in glioma. Overall, our results suggest that HSPB1 may regulate the function of immune cells, serve as a new immunotherapy target, and predict the response to immunotherapy in patients with GBM.Conclusion: HSPB1 appears to serve as a potential predictor of the clinical prognosis and response to immunotherapy in patients with GBM. It may be possible to identify patients who are likely to benefit from immunotherapy by assessing the expression level of HSPB1.","PeriodicalId":16544,"journal":{"name":"Journal of neurological surgery. Part A, Central European neurosurgery","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neurological surgery. Part A, Central European neurosurgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/s-0043-1777761","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Glioblastoma multiforme (GBM) is a highly aggressive form of brain cancer. This study investigated the clinical predictive value of heat shock protein β1 (HSPB1) in patients with GBM.

Methods: A correlation was established between HSPB1 expression and GBM progression using data from The Cancer Genome Atlas (TCGA) dataset, Chinese Glioma Genome Atlas dataset, Gene Expression Omnibus dataset, and Human Protein Atlas database. A survival analysis was conducted and an HSPB1-based nomogram was constructed to evaluate the prognostic value of HSPB1 in patients with GBM.

Results: Based on TCGA data mining, we discovered that HSPB1 was significantly elevated in patients with GBM and may reflect their response to immunotherapy. In survival analysis, it appeared to have a predictive role in the prognosis of patients with GBM. Five signaling pathways were significantly enriched in the high HSPB1 expression phenotype according to the gene set enrichment analysis. In addition, a significant association was found between HSPB1 expression and immune checkpoints, tumor immune infiltration, tumor immune microenvironment, and immune cell markers in glioma. Overall, our results suggest that HSPB1 may regulate the function of immune cells, serve as a new immunotherapy target, and predict the response to immunotherapy in patients with GBM.

Conclusion: HSPB1 appears to serve as a potential predictor of the clinical prognosis and response to immunotherapy in patients with GBM. It may be possible to identify patients who are likely to benefit from immunotherapy by assessing the expression level of HSPB1.

查看原文本刊更多论文

HSPB1 表达升高与多形性胶质母细胞瘤患者预后不良有关。

背景：多形性胶质母细胞瘤（GBM多形性胶质母细胞瘤（GBM）是一种侵袭性极强的脑癌。本研究调查了热休克蛋白β1（HSPB1）在GBM患者中的临床预测价值：方法：利用癌症基因组图谱（TCGA）数据集、中国胶质瘤基因组图谱数据集、基因表达总库数据集和人类蛋白质图谱数据库中的数据，建立 HSPB1 表达与 GBM 进展之间的相关性。我们进行了生存分析，并构建了基于HSPB1的提名图，以评估HSPB1在GBM患者中的预后价值：基于TCGA数据挖掘，我们发现HSPB1在GBM患者中明显升高，可能反映了他们对免疫疗法的反应。在生存分析中，HSPB1似乎对GBM患者的预后具有预测作用。根据基因组富集分析，在 HSPB1 高表达表型中，有五个信号通路明显富集。此外，HSPB1的表达与胶质瘤中的免疫检查点、肿瘤免疫浸润、肿瘤免疫微环境和免疫细胞标记物之间也有明显的关联。总之，我们的研究结果表明，HSPB1可能会调节免疫细胞的功能，成为新的免疫治疗靶点，并预测GBM患者对免疫治疗的反应：结论：HSPB1似乎可以预测GBM患者的临床预后和对免疫疗法的反应。结论：HSPB1似乎可以预测GBM患者的临床预后和对免疫疗法的反应，通过评估HSPB1的表达水平，有可能识别出可能从免疫疗法中获益的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of neurological surgery. Part A, Central European neurosurgery CLINICAL NEUROLOGY-SURGERY

CiteScore

2.30

自引率

0.00%

发文量

期刊介绍： The Journal of Neurological Surgery Part A: Central European Neurosurgery (JNLS A) is a major publication from the world''s leading publisher in neurosurgery. JNLS A currently serves as the official organ of several national neurosurgery societies. JNLS A is a peer-reviewed journal publishing original research, review articles, and technical notes covering all aspects of neurological surgery. The focus of JNLS A includes microsurgery as well as the latest minimally invasive techniques, such as stereotactic-guided surgery, endoscopy, and endovascular procedures. JNLS A covers purely neurosurgical topics.